100 questions que l'on nous pose, 2012. ,
Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes, Marketing Science, vol.28, issue.4, pp.690-708, 2009. ,
DOI : 10.1287/mksc.1080.0440
Product lifecycle management: marketing strategies for the pharmaceutical industry, Journal of Medical Marketing, vol.330, issue.4, pp.293-301, 2008. ,
DOI : 10.1057/jmm.2008.23
Living Twice: How a Product Goes through Multiple Life Cycles*, Journal of Product Innovation Management, vol.43, issue.(4, pp.797-827, 2010. ,
DOI : 10.1111/j.1540-5885.2010.00753.x
URL : https://lra.le.ac.uk/bitstream/2381/32025/2/John%20-%20LIVING%20AT%20LEAST%20TWICE%20-%20v6_14-6-2010_John%20updated_Juli_2010.3.pdf
Competitiveness in follow-on drug R&D: a race or imitation?, Nature Reviews Drug Discovery, vol.10, pp.23-27, 2011. ,
Pharmaceutical product differentiation: A strategy for strengthening product pipeline and life cycle management, Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, pp.104-118, 2009. ,
Adalat?A Lifecycle Managed Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, pp.187-200, 2009. ,
How to improve R&D productivity: the pharmaceutical industry's grand challenge, Nature Reviews Drug Discovery, vol.116, issue.3, pp.201-215, 2010. ,
DOI : 10.1038/nrd3078
The productivity crisis in pharmaceutical R&D, Nature Reviews Drug Discovery, vol.23, issue.6, pp.428-466, 2011. ,
DOI : 10.1038/nrd3405
The Adoption of Radical and Incremental Innovations: An Empirical Analysis, Management Science, vol.32, issue.11, pp.1422-1455, 1986. ,
DOI : 10.1287/mnsc.32.11.1422
Estimating the cost of new drug development: is it really $802 Million? Health Affairs, pp.420-448, 2006. ,
The cost of biopharmaceutical R&D: is biotech different?, Managerial and Decision Economics, vol.13, issue.4-5, pp.469-79, 2007. ,
DOI : 10.1002/mde.1360
The Continuing Evolution of the Pharmaceutical Industry: Career Challenges and Opportunities, 2012. ,
Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy, Neurological Sciences, vol.30, issue.Suppl 451, pp.299-306, 2010. ,
DOI : 10.1007/s10072-009-0211-y
Product market definition in the pharmaceutical industry, Antitrust Law Journal, issue.271, pp.633-76, 2003. ,
Drug developer strategies to boost competitiveness, Nature Reviews: Drug Discovery, vol.6, pp.265-66, 2007. ,
Les Biosimilaires ne sont pas des génériques. Caduceus express, 2009. ,
Competitiveness in follow-on drug R&D: a race or imitation?, Nature Reviews Drug Discovery, vol.10, pp.23-27, 2011. ,
Mergers and acquisitions in the pharmaceutical and biotech industries, Managerial and Decision Economics, vol.33, issue.4-5, pp.307-328, 2007. ,
DOI : 10.1002/mde.1343
Specific features of pharmaceuticals marketing mix Journal of Management & Marketing in Healthcare, pp.160-167, 2011. ,
Characteristics of Physicians Targeted by the Pharmaceutical Industry to Participate in E-detailing, Health Marketing Quarterly, vol.155, issue.2, pp.98-116, 2009. ,
DOI : 10.1377/hlthaff.5.3.91
Changing channels Medical Marketing & Media, pp.34-42, 2005. ,
Drug promotion: what we know, what we have yet to learn. Reviews of materials in the WHO ,
eLearning in continuing medical education: A comparison of knowledge gain and learning efficiency, Journal of Medical Marketing, vol.9, issue.2, pp.156-161, 2009. ,
DOI : 10.1057/jmm.2009.5
Benchmarking web based CRM strategies of pharmaceutical companies : a competitive analysis using analytic hierarchy process. Health Care and Pharmaceutical Management, pp.417-422 ,
The CRM?physician interface: Toward a model of physician relationship building Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, pp.316-323, 2005. ,
8:;D.0:79;.-! ;8O;D;:19! :/D790/-1B;B! 3!, pp.79-82 ,
30! 3;47823!8, :),%(* D2":*E(1"2*F(#".),G:),%(* "#$! %&'(9(:! +,-./01$--23%(* D2":*E(1"2*F%(* D2":*E(1"2*F%(* "#$! %&'L)>L! +!;.4.!;,B!87/!6..8!C2B357B.C!7W8!-74!,BB./B!28!S;,B.!EEE!,8C!6.078CV! ! Annex, pp.5-26425528 ,